Our clinical research activities include genetic, imaging (such as PET/MRI), electrophysiological and biomarker studies, as well as phase I-III clinical trials. Our basic research focuses on the generation of patient-derived stem cell models for ALS and FTD to study disease mechanisms. We also use these models to identify and validate molecular targets for new treatments.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.